Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3

Go back to Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3
(NASDAQ: ALMS) Delayed: 6.78 -0.04 (0.59%)
Previous Close $6.82    52 Week High $ 
Open $6.68    52 Week Low $ 
Day High $6.83    P/E N/A 
Day Low $6.48    EPS $ 
Volume 1,230,177